<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456466</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2303-I-01</org_study_id>
    <nct_id>NCT03456466</nct_id>
  </id_info>
  <brief_title>Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel Control Clinical Trial to Assess the Similarity of the Safety and Pharmacokinetics of TQB2303 in Combination With Rituximab to Patients With AggressiveCD20 Positive Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Outcome Measures:

      Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ]

      Secondary Outcome Measures:

      The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The
      area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-∞); The
      time to reach the maximum plasma concentration after treatment (Tmax) Total clearance (CL);
      Elimination of half-life (t1 / 2); Apparent distribution volume (Vd).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>TQB2303 and Rituximab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>85 days</time_frame>
    <description>Area under the curve (AUC) forTQB2303 and rituximab concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>85 days</time_frame>
    <description>The Maximum Concentration (Cmax) of the TQB2303 and rituximab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>85 days</time_frame>
    <description>The area under the plasma concentration-time curve from 0 to inf (infinite) time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>85 days</time_frame>
    <description>The time to reach the maximum plasma concentration after treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL</measure>
    <time_frame>85 days</time_frame>
    <description>Total clearance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2</measure>
    <time_frame>85 days</time_frame>
    <description>Elimination of half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd</measure>
    <time_frame>85 days</time_frame>
    <description>Apparent distribution volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunogenicity</measure>
    <time_frame>85 days</time_frame>
    <description>Anti-drug antibody (ADA), neutralizing antibody (Nab detection when ADA positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CD19+ CD20+ B-cells from baseline</measure>
    <time_frame>85 days</time_frame>
    <description>Change of CD19+ CD20+ B-cells from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Non-hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>TQB2303</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2303</intervention_name>
    <description>375mg/m2 ，iv</description>
    <arm_group_label>TQB2303</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 ，iv</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients should participate in the study voluntarily and sign informed consent;

          2. CD20-positive non-Hodgkin's lymphoma (NHL)：Diffuse Large B-cell Lymphoma；Mantle Cell
             Lymphoma；Follicular Lymphoma；Marginal Zone Lymphoma;

          3. having obtained CR (complete remission) or CRu (uncertain complete remisson) after the
             prior therapy;And the investigators believe that CD20-positive B-cell NHL patients can
             benefit from anti-CD20 monoclonal antibody therapy;

          4. aged from 18 to 75 years;

          5. ECOG PS:0-1；

          6. Life expectancy of more than 3 months

        Exclusion Criteria:

          1. Had received rituximab or other anti-CD20(+) monoclonal antibody treatment within 1
             year before enrollment;

          2. patients who were treated with antitumor therapy (including corticosteroid therapy)
             within 4 weeks prior to enrollment, or who had not recovered from the toxicity of the
             previous treatment;

          3. Patients who participated in other clinical studies within 30 days ;

          4. Serious hematologic dysfunction (white blood cell count of &lt;3.0×10^9/L; absolute
             neutrophil count of &lt;1.5×10^9/L; platelet count of &lt; 75×10^9/L; hemoglobin level of
             &lt;80g/L); In the absence of anticoagulant therapy, International Standardization Ratio
             (INR)&gt; 1.5× ULN;Partial prothrombin time (PTT)Or activated partial thromboplastin time
             (aPTT)&gt; 1.5 × ULN;) Hepatic dysfunction (total bilirubin level of &gt; 1.5 × upper limit
             of normal (ULN); aspartate amino transferase (AST) and alanine amino transferase (ALT)
             levels of &gt; 2.0 × ULN;) renal dysfunction (serum creatinine level of &gt; 1.5×ULN );

          5. Other invasive malignancies except for cured the IB or lower level of cervical cancer;
             Non-invasive basal cells or squamous cell skin cancer; Get CR&gt; 10 years of breast
             cancer;Get CR&gt; 10 years of malignant melanoma;or other malignancies with CR&gt; 5 years;

          6. Central nervous system (CNS) lymphoma, AIDS-associated lymphoma;

          7. Active infections and other serious non-malignant tumor diseases, Such as Qualitative
             pneumonia, Severe organic cardiovascular disease, Heart conduction block ＞
             2,Myocardial infarction in 6 months, Cerebral infarction in 3 months,Cerebral
             hemorrhage,Thyroid dysfunction (TSH lower than the normal lower limit or higher than
             the upper limit of normal, and the researchers have a clinical significance);

          8. Seropositive for HIV , HCV antibody; Or one of the following HBV findings :

               1. HBsAg positive;

               2. HBsAg negative, HBcAb positive and HBV DNA positive;

          9. Plan major surgery, or surgical wound unhealed patients;

         10. History of severe allergies, protein products and mouse products such as allergies;

         11. Pregnancy or breast feeding. Companion for women of childbearing age or women of
             childbearing age,who reluctant to take appropriate contraceptive methods within one
             year after the last treatment of the study;Pregnancy before pregnancy screening, the
             women who blood / urine results were positive;

         12. Receipt of a live/attenuated vaccine within 4 weeks prior to the Screening Visit;

         13. Researchers think that do not fit into the group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng feng, doctor</last_name>
      <phone>025-83233303</phone>
      <email>fjif@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Depei wu, doctor</last_name>
      <phone>0512-67780040</phone>
      <email>drwudepei@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

